Possible excess quantities of semaglutide and tirzepatide by all Sub-ICB Locations
Why it matters: Semaglutide and tirzepatide are both used mainly to treat diabetes. Semaglutide injection is used weekly and is only available as a multidose pre-filled pen, each of which contains four doses so one multidose pen will last for one month. Tirzepatide is used weekly and is licensed in both a single-use and a multidose pre-filled pen form. The tirzepatide multidose pen contains four doses so one multidose pen will last for one month.
There have been some reports that prescribers are requesting four multidose pens per month in error. This is unlikely to be required and likely to be caused by the dose and quantity being confused on a picking list.
Description: Total quantity where a prescription is for four pens per prescription as a proportion of all semaglutide and tirzepatide prescribing
Explore:
Tagged as: Standard, Cost Saving, Diabetes, Safety (or browse all measures)
Sub-ICB Locations are ordered by mean percentile over the past six months. Each chart shows the results for the individual Sub-ICB Location, plus deciles across all Sub-ICB Locations in the NHS in England.
View measure for NHS England combined →
Fetching data...